Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Dulaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 26 Jun 2023 Primary endpoint (the change in visceral adipose tissue) has not been met according to results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 11 Jul 2022 Status changed from recruiting to completed.